Wegovy vs Saxenda: Which Weight Loss Treatment is Better?

If you have been researching weight loss injections in the UK, you have probably come across two popular names that keep appearing in conversations, forums and pharmacy websites. Wegovy and Saxenda are both prescription medications designed to help people lose weight, but they work differently and produce varying results for different individuals. Choosing between them can feel overwhelming, especially when you are already struggling with the emotional and physical challenges of managing your weight. The good news is that understanding how each medication works, what results you can realistically expect, and which one might suit your lifestyle better can make this decision much clearer and help you take a confident step forward on your weight loss journey.

Quick Summary

Wegovy and Saxenda are both GLP-1 receptor agonist medications prescribed for weight management in the UK, but they contain different active ingredients and produce different results. Understanding their key differences helps you make an informed choice about which treatment might work better for your specific situation.

• Wegovy contains semaglutide and is injected once weekly, whilst Saxenda contains liraglutide and requires daily injections
• Clinical trials show Wegovy typically produces 15% average body weight loss compared to Saxenda's 8% over similar treatment periods
• Both medications work by reducing appetite and slowing gastric emptying, but Wegovy has a longer duration of action
• Side effects are similar for both treatments, primarily affecting the gastrointestinal system during initial weeks
• Cost and availability vary between the two medications, with Wegovy generally being more expensive but requiring fewer injections

Table of Contents

• Understanding Wegovy and Saxenda: How Each Medication Works
• Clinical Effectiveness: Comparing Weight Loss Results
• Side Effects and Tolerability: What to Expect
• Dosing Schedules and Convenience Factors
• Cost Comparison and UK Availability
• Choosing the Right Treatment for Your Needs
• Key Takeaways
• When to Seek Professional Advice
• Frequently Asked Questions

Understanding Wegovy and Saxenda: How Each Medication Works

Before diving into the comparison, it helps to understand that both Wegovy and Saxenda belong to a class of medications called GLP-1 receptor agonists. These drugs mimic a natural hormone called glucagon-like peptide-1, which your body produces in response to eating. This hormone plays a crucial role in regulating appetite, blood sugar levels and the speed at which food moves through your digestive system. When you take either medication, you are essentially enhancing your body's natural satiety signals, making it easier to eat less without feeling constantly deprived or hungry.

Wegovy contains the active ingredient semaglutide, which was originally developed for diabetes management under the brand name Ozempic. The weight loss formulation was approved specifically for chronic weight management after extensive clinical trials demonstrated its remarkable effectiveness. Semaglutide works by binding to GLP-1 receptors in the brain's appetite control centres, reducing hunger signals and increasing feelings of fullness after smaller meals. If you want to understand how long it takes for GLP-1 medications to start working, the effects typically begin within the first few weeks of treatment.

Saxenda, on the other hand, contains liraglutide as its active ingredient. Like semaglutide, liraglutide was first used for diabetes treatment before being repurposed for weight management. The key difference lies in how long each medication stays active in your body. Liraglutide has a shorter half-life, meaning it breaks down more quickly and requires daily administration to maintain therapeutic levels. Both medications effectively slow gastric emptying, which means food stays in your stomach longer, contributing to prolonged feelings of satisfaction after eating.

The mechanism of action for both drugs extends beyond simple appetite suppression. They also influence how your brain responds to food cues and reward signals, potentially reducing cravings for high-calorie foods. Some research suggests these medications may help rewire eating behaviours over time, making healthy choices feel more natural and sustainable even after treatment ends.

• Both medications are GLP-1 receptor agonists that mimic natural satiety hormones
• Wegovy uses semaglutide with a longer duration of action requiring weekly injections
• Saxenda uses liraglutide which requires daily administration due to shorter half-life
• Both work on appetite centres in the brain and slow gastric emptying
• The medications may help modify long-term eating behaviours beyond simple appetite reduction

Clinical Effectiveness: Comparing Weight Loss Results

When choosing between weight loss treatments, the most pressing question on everyone's mind is naturally about results. Clinical trial data provides valuable insights into what you might realistically expect from each medication, though individual responses always vary. The STEP trials investigating Wegovy and the SCALE trials examining Saxenda offer the most comprehensive comparisons available, involving thousands of participants over extended periods.

The landmark STEP 1 trial followed participants taking Wegovy for 68 weeks alongside lifestyle modifications. The results were impressive: participants lost an average of 14.9% of their body weight compared to just 2.4% in the placebo group. For someone weighing 100 kilograms, this translates to nearly 15 kilograms of weight loss. Perhaps more importantly, over a third of participants achieved weight loss of 20% or more, a threshold previously only attainable through bariatric surgery for most people.

Saxenda's SCALE Obesity and Prediabetes trial showed meaningful but more modest results. Over 56 weeks, participants achieved an average weight loss of approximately 8% of their starting body weight, compared to 2.6% with placebo. While this represents significant progress for many individuals, the difference from Wegovy's results is notable. However, it is worth remembering that any meaningful weight loss brings health benefits, and some people respond better to Saxenda than average figures suggest.

Beyond the numbers on the scale, both medications demonstrate benefits for metabolic health markers. Improvements in blood pressure, cholesterol levels and blood sugar control have been documented with both treatments. For individuals with prediabetes, these medications can reduce the progression to type 2 diabetes. Many people also experience improvements in quality of life, mobility and confidence that cannot be captured by weight statistics alone. Understanding why Wegovy might not be working for some individuals can help set realistic expectations.

• Wegovy clinical trials showed average weight loss of approximately 15% over 68 weeks
• Saxenda trials demonstrated average weight loss of around 8% over 56 weeks
• Over 35% of Wegovy users achieved 20% or greater weight loss in studies
• Both medications improve metabolic markers including blood pressure and cholesterol
• Individual responses vary significantly, and some people respond better to one medication than the other

Side Effects and Tolerability: What to Expect

Starting any new medication naturally raises concerns about potential side effects, and both Wegovy and Saxenda share similar profiles in this regard. The most common side effects are gastrointestinal in nature, which makes sense given how these medications work by affecting your digestive system. Understanding what to expect and how to manage these effects can significantly improve your treatment experience and help you stay the course when things feel challenging initially.

Nausea is the most frequently reported side effect for both medications, particularly during the dose escalation phase when your body is adjusting to the treatment. Most people find that nausea is mild to moderate and improves substantially after the first few weeks. Eating smaller, more frequent meals, avoiding fatty or greasy foods, and staying well hydrated can all help manage this symptom. Some patients find that taking their injection in the evening allows them to sleep through the worst of any nausea. Learning about normal side effects when starting GLP-1 treatment can provide reassurance during this adjustment period.

Other common gastrointestinal effects include diarrhoea, constipation, vomiting and abdominal discomfort. These typically occur more frequently in the early stages of treatment and tend to diminish over time as your body adapts. Constipation in particular can be managed with adequate fibre intake and hydration. Some people report injection site reactions such as redness or itching, though these are generally mild and temporary.

More serious side effects are rare but important to be aware of. Both medications carry warnings about potential pancreatitis, and patients should seek immediate medical attention if they experience severe, persistent abdominal pain. There are also precautions for individuals with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, as these conditions contraindicate GLP-1 agonist use. Gallbladder problems, including gallstones, have been reported with both medications, likely related to rapid weight loss rather than the drugs themselves.

• Nausea is the most common side effect, usually improving after initial weeks
• Gastrointestinal effects including diarrhoea, constipation and abdominal pain are common initially
• Side effects typically reduce as the body adjusts to treatment over time
• Serious side effects like pancreatitis are rare but require immediate medical attention
• Injection site reactions are generally mild and temporary for both medications

Dosing Schedules and Convenience Factors

One of the most significant practical differences between Wegovy and Saxenda lies in their dosing schedules, which can have a meaningful impact on treatment adherence and quality of life. For many busy people juggling work, family and social commitments, the frequency of injections can be a deciding factor in which treatment feels more manageable long-term.

Wegovy is administered once weekly, which many patients find considerably more convenient than daily injections. You choose a consistent day of the week for your injection and can take it at any time of day, with or without food. The weekly schedule means only 52 injections per year rather than 365, reducing the mental burden of daily treatment and making it easier to maintain consistency. This can be particularly helpful when travelling or during busy periods when maintaining daily routines becomes challenging.

Saxenda requires daily injections, which some people find easier to incorporate into existing daily routines like brushing teeth or taking other medications. The daily schedule provides more flexibility if you need to adjust timing for special events or if you forget a dose, as missing one day has less impact than missing a weekly injection. However, the daily requirement can feel burdensome over time, and some patients struggle with adherence, which directly impacts effectiveness. Understanding how long a Saxenda pen lasts helps with planning and budgeting for treatment.

Both medications use pre-filled injection pens that are designed for easy self-administration. The injection technique is straightforward, and most people become comfortable with the process quickly. Wegovy pens come in fixed doses corresponding to each phase of the titration schedule, whilst Saxenda pens allow dose adjustment using a dial mechanism. Storage requirements are similar for both, requiring refrigeration before first use and allowing room temperature storage for a limited period after opening.

• Wegovy requires only one injection per week on a chosen consistent day
• Saxenda requires daily injections, offering more flexibility but higher frequency
• Weekly dosing may improve long-term adherence for many patients
• Both use simple pre-filled pen systems designed for self-administration
• Storage requirements are similar, with refrigeration needed before first use

Cost Comparison and UK Availability

Financial considerations often play a significant role in treatment decisions, particularly for long-term medications that may be needed for extended periods. Both Wegovy and Saxenda are available through the NHS under specific criteria, but many patients opt for private prescriptions to access treatment more quickly or if they do not meet NHS eligibility requirements. Understanding the cost landscape helps you plan appropriately and explore all available options.

Private prescription costs for Wegovy typically range from approximately £150 to £250 per month depending on the dose and pharmacy, whilst Saxenda generally costs between £180 and £280 monthly. These figures vary between providers and may change over time as supply situations evolve. When comparing costs, remember that Wegovy's higher effectiveness may translate to reaching your goal weight faster, potentially reducing overall treatment duration and total expenditure.

NHS availability for both medications exists but comes with stringent eligibility criteria. Generally, you need a BMI of 35 or above with weight-related health conditions, or 30 or above with specific comorbidities, along with evidence of previous structured weight management attempts. Access through specialist weight management services is typically required, and waiting lists can be lengthy in many areas. If you are exploring NHS options, understanding how to get Wegovy on the NHS provides detailed guidance on the process.

Supply issues have affected both medications at various times since their launch, with Wegovy experiencing notable shortages during periods of high demand. This practical consideration may influence which medication you choose, as consistent supply is essential for maintaining treatment momentum. Discussing availability with your pharmacy before starting treatment helps avoid frustrating interruptions.

• Private Wegovy prescriptions typically cost £150-250 monthly depending on dose
• Saxenda private costs generally range from £180-280 per month
• NHS availability exists but requires meeting strict eligibility criteria
• Supply can vary for both medications, with periodic shortages possible
• Higher effectiveness of Wegovy may offset cost differences through shorter treatment duration

Choosing the Right Treatment for Your Needs

Selecting between Wegovy and Saxenda ultimately depends on your individual circumstances, preferences and health profile. There is no universally correct answer, and what works brilliantly for one person may not be the ideal choice for another. Working with a healthcare professional who understands your complete medical history and weight loss goals helps ensure you make the most appropriate choice for your situation.

If maximum weight loss potential is your primary goal and you prefer the convenience of weekly injections, Wegovy may be the better choice. Its superior efficacy in clinical trials makes it particularly suitable for individuals with higher BMIs or those who have struggled with more modest weight loss approaches in the past. The weekly dosing schedule suits people who find daily medication routines difficult to maintain consistently.

Saxenda might be preferable if you have specific medical considerations that favour liraglutide, if you prefer daily dosing for routine integration, or if Wegovy is unavailable or unaffordable for your circumstances. Some patients who have not tolerated semaglutide well find that liraglutide suits them better, and vice versa. The daily dosing also allows for more flexible timing adjustments when needed.

Consider your lifestyle factors carefully when making this decision. If you travel frequently for work, weekly injections may be significantly easier to manage. If you have a established morning routine and prefer spreading medication through daily micro-actions, Saxenda might feel more natural. Your healthcare provider can also help identify any medical factors that might make one medication more suitable than the other based on your health history.

Feature	Wegovy	Saxenda
Active Ingredient	Semaglutide	Liraglutide
Injection Frequency	Once weekly	Once daily
Average Weight Loss	Approximately 15%	Approximately 8%
Maximum Dose	2.4mg weekly	3.0mg daily
Titration Period	16-20 weeks	4-5 weeks
Approximate Monthly Cost (Private)	£150-250	£180-280
Time on UK Market	Since 2022	Since 2017
Common Side Effects	Nausea, diarrhoea, constipation	Nausea, diarrhoea, constipation

• Choose Wegovy for maximum efficacy and weekly convenience if circumstances allow
• Consider Saxenda if daily dosing suits your routine or Wegovy is unavailable
• Medical history and tolerability may favour one medication over the other
• Lifestyle factors including travel and daily routines should influence your choice
• Working with a healthcare professional ensures the most appropriate selection

Key Takeaways

• Wegovy produces significantly greater average weight loss (15%) compared to Saxenda (8%) in clinical trials, though individual results vary
• Weekly Wegovy injections offer more convenience than daily Saxenda injections for most patients
• Both medications share similar gastrointestinal side effects that typically improve over time
• Cost is comparable between the two treatments, with Wegovy's higher efficacy potentially offsetting any price differences
• The right choice depends on individual factors including medical history, lifestyle preferences and access to each medication

When to Seek Professional Advice

While this guide provides comprehensive information about both medications, it is essential to consult with a qualified healthcare professional before starting either treatment. A prescriber can assess whether you are a suitable candidate based on your BMI, medical history, current medications and weight loss goals. They can also monitor your progress and adjust treatment as needed.

Seek immediate medical attention if you experience severe or persistent abdominal pain, which could indicate pancreatitis. Contact your healthcare provider if side effects are significantly impacting your quality of life, if you are not seeing expected results after several months of treatment, or if you have concerns about interactions with other medications you are taking.

Regular follow-up appointments are important throughout treatment to assess effectiveness, manage side effects and make any necessary adjustments. Your healthcare team can also provide valuable support for the dietary and lifestyle changes that maximise results from these medications. Remember that these drugs work best as part of a comprehensive approach to weight management including healthy eating and physical activity.

Frequently Asked Questions

Is Wegovy stronger than Saxenda for weight loss?
Yes, clinical trials show Wegovy produces greater average weight loss (around 15%) compared to Saxenda (around 8%), making it the more potent option for most patients.

Can I switch from Saxenda to Wegovy?
Yes, switching is possible with medical supervision, though your prescriber will likely recommend a washout period and careful dose titration when starting Wegovy.

Which has fewer side effects, Wegovy or Saxenda?
Both medications have similar gastrointestinal side effects, though some patients tolerate one better than the other due to individual differences in metabolism and sensitivity.

Are Wegovy and Saxenda available on the NHS?
Both medications have NHS availability but with strict eligibility criteria based on BMI, weight-related health conditions and previous weight management attempts through specialist services.

Scientific References

• NICE Technology Appraisal Guidance on Semaglutide for Managing Overweight and Obesity
• Electronic Medicines Compendium - Wegovy Summary of Product Characteristics
• NHS Information on Liraglutide for Weight Management